Avizakimab - Boston Pharmaceuticals
Alternative Names: BOS-161721Latest Information Update: 31 Oct 2021
At a glance
- Originator MedImmune
- Developer Boston Pharmaceuticals
- Class Monoclonal antibodies
- Mechanism of Action Interleukin 21 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Systemic lupus erythematosus
- No development reported Autoimmune disorders
Most Recent Events
- 16 Nov 2020 Boston Pharmaceuticals completes a phase Ib/II trial in Systemic lupus erythematosus (In adults, In the elderly) in USA, Ukraine, Romania, Poland, Philippines, Peru, Mexico, Hungary, Georgia, Colombia, Bulgaria and Argentina (SC) (NCT03371251)
- 27 Oct 2020 Phase I/II trial for Systemic lupus erythematosus (In adults, In the elderly) is still ongoing in USA (NCT03371251)
- 16 Apr 2020 Boston Pharmaceuticals completes enrolment in a phase I/II trial in Systemic lupus erythematosus (In adults, In the elderly) in USA, Ukraine, Romania, Poland, Philippines, Peru, Mexico, Hungary, Georgia, Colombia, Bulgaria, Argentina (SC), (NCT03371251)